Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GGB Awards Returns To Barcelona In Its 10th Year

Event Reaches 10th Anniversary Milestone With Ceremony On Wednesday 25 October

Executive Summary

Celebrating its tenth anniversary year, the Global Generics & Biosimilars Awards 2023 will take place on Wednesday 25 October in Barcelona, Spain.

Nominations are now open for the Global Generics & Biosimilars Awards 2023, which has today been officially launched by Citeline and will take place on Wednesday 25 October at the Hotel Porta Fira, Barcelona, Spain.

This year marks a milestone for the Awards – which are free to enter and attend – as the event marks its tenth year of recognizing and promoting achievements across the generics, biosimilars, and value-added medicines industries. This year, the Awards are once again supported by our headline sponsor, IQVIA, and supported by International Health Partners and the International Generic and Biosimilar Medicines Association.

The deadline for entries is 4 September 2023, and nominations can cover any activities that took place between 1 August 2022 and 31 August 2023.

Full details of the Global Generics & Biosimilars Awards 2023 – including more information on how to enter – are available here.

Entries in previous years have all been great examples of the difference that the off-patent industry makes every day in making more affordable treatments more accessible to ever more people around the world, and after some record years in terms of entries we expect the standard of submissions to be just as high this year.

Spanning 14 different categories, the Global Generics & Biosimilars Awards covers an array of industry activities. This year, we are introducing a new category recognizing promotional campaigns in addition to our 13 other regular categories.

Alongside the global and regional Company of the Year awards – recognizing the world leader as well as top companies in the EMEA, Americas and Asia-Pacific regions – our categories also include Business Development of the Year, Acquisition of the Year and Industry Partner of the Year, while other specific categories also cover Biosimilars and Value Added Medicines. Outstanding achievements in company leadership and corporate social responsibility are also honored during the ceremony.

We look forward to welcoming entrants and attendees alike to the Global Generics & Biosimilars Awards in Barcelona this October, and it is certain that our panel of distinguished judges will have a tougher task than ever in selecting the winners from such a competitive field.

Full details of last year’s winners are available here.

To enquire about sponsorship opportunities for the Global Generics & Biosimilars Awards 2023, please e-mail [email protected]

And to register interest in attending the Global Generics & Biosimilars Awards 2023, to receive the latest updates and for any further details, please e-mail [email protected]

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel